Cardiotoxicity of antitumor agents
References (45)
- et al.
Dose-effect and structure-function relationships in doxorubicin cardiomyopathy
Am Heart J
(1981) - et al.
Early anthracycline cardiotoxicity
Am J Med
(1978) - et al.
Histamine-mediated myocardial damage in rabbits
J Mol Cell Cardiol
(1982) - et al.
Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity
Am Heart J
(1983) - et al.
Adriamycin cardiotoxicity: possible pathogenic mechanisms
J Mol Cell Cardiol
(1981) - et al.
Inhibition of coenzyme Q10-enzymes, succinoxidase and NADH-oxidase, by adriamycin and other quinones having antitumor activity
Biochem Biophys Res Commun
(1974) - et al.
Selective inhibition of rat and human cardiac guanylate cyclase in vitro by Doxorubicin (Adriamycin): possible link to anthracycline cardiotoxicity
J Mol Cell Cardiol
(1979) - et al.
Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity
Lancet
(1976) - et al.
5-fluorouracil and angina
Lancet
(1975) - et al.
A clinicopathologic analysis of Adriamycin cardiotoxicity
Cancer
(1973)
Efficacy and cost of cardiac monitoring in patients receiving doxorubicin
Cancer
(1982)
Anthracycline cardiomyopathy monitored by morphologic changes
Cancer Treat Rep
(1978)
Clinical spectrum of anthracycline antibiotic cardiotoxicity
Cancer Treat Rep
(1978)
Doxorubicin cardiomyopathy: Evaluation by phonocardiograhpy, endomyocardial biopsy, and cardiac catheterization
Ann Intern Med
(1978)
Risk factors for doxorubicin-induced congestive heart failure
Ann Intern Med
(1979)
Delayed and progressive myocardial lesions after Adriamycin administration in the rabbit
Cancer Res
(1976)
An anthracycline antibiotic-induced cardiomyopathy in rabbits
Lab Invest
(1974)
Pathologic feature of adriamycin toxicosis in young pigs: nonskeletal lesions
Am J Vet Res
(1979)
Anthracycline-associated cardiac and renal damage in rabbits. Evidence for mediation by vasoactive substances
Lab Invest
(1981)
Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography
N Engl J Med
(1979)
Anthracycline cardiotoxicity: clinical and pathologic outcomes assessed by radionuclide ejection fraction
Cancer
(1980)
Cited by (90)
Role of carnitine in cancer chemotherapy-induced multiple organ toxicity
2010, Saudi Pharmaceutical JournalCitation Excerpt :It has a broad-spectrum antitumour activity against a variety of hematological and solid tumours (Carter, 1975). Unfortunately, the chronic administration of DOX is associated with the development of dose-dependent and irreversible cardiomyopathy, which restricts its usefulness in cancer chemotherapy (Goormaghtih and Ruysschaert, 1984; Kantrowitz and Bristow, 1984; Buzadar et al., 1985). Cardiomyopathy is the major limiting complication of DOX and affects 30–40% of the patients who receive a cumulative dose more than 500 mg/m2 (Van Vleet et al., 1980; Lefrak et al., 1973).
Inhibition of gene expression of heart fatty acid binding protein and organic cation/carnitine transporter in doxorubicin cardiomyopathic rat model
2010, European Journal of PharmacologyCardiological aspects of systemic disease
2010, Paediatric CardiologyEffect of methimazole treatment on doxorubicin-induced cardiotoxicity in mice
2009, Food and Chemical ToxicologyPropionyl-L-carnitine as protector against adriamycin-induced cardiomyopathy
2001, Pharmacological ResearchModulation of anthracycline activity in canine mammary tumour cells in vitro by medroxyprogesterone acetate
2000, Research in Veterinary Science
Copyright © 1984 Published by Elsevier Inc.